A detailed history of Met Life Investment Management, LLC transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Met Life Investment Management, LLC holds 65,326 shares of ADPT stock, worth $331,856. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65,326
Previous 65,326 -0.0%
Holding current value
$331,856
Previous $236,000 41.53%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.34 - $3.96 $17,587 - $29,763
7,516 Added 13.0%
65,326 $236,000
Q1 2024

May 14, 2024

BUY
$2.88 - $4.8 $166,492 - $277,488
57,810 New
57,810 $185,000
Q2 2023

Apr 29, 2024

BUY
$6.19 - $8.78 $360,666 - $511,575
58,266 New
58,266 $390,000
Q1 2023

May 09, 2024

BUY
$7.8 - $10.11 $454,474 - $589,069
58,266 New
58,266 $514 Million
Q2 2022

May 10, 2024

BUY
$6.4 - $14.73 $331,238 - $762,365
51,756 Added 795.02%
58,266 $471,000
Q2 2022

Mar 22, 2023

BUY
$6.4 - $14.73 $331,238 - $762,365
51,756 Added 795.02%
58,266 $471,000
Q2 2022

Aug 11, 2022

BUY
$6.4 - $14.73 $331,238 - $762,365
51,756 Added 795.02%
58,266 $471,000
Q1 2022

May 10, 2024

BUY
$10.12 - $28.9 $65,881 - $188,139
6,510 New
6,510 $90,000
Q1 2022

Jun 20, 2023

SELL
$10.12 - $28.9 $523,770 - $1.5 Million
-51,756 Reduced 88.83%
6,510 $90,000
Q1 2022

Mar 22, 2023

BUY
$10.12 - $28.9 $63,502 - $181,347
6,275 Added 2670.21%
6,510 $90,000
Q1 2022

May 12, 2022

BUY
$10.12 - $28.9 $65,881 - $188,139
6,510 New
6,510 $90,000
Q4 2021

Feb 15, 2022

SELL
$25.17 - $36.85 $5,914 - $8,659
-235 Closed
0 $0
Q3 2021

Mar 22, 2023

SELL
$30.02 - $39.87 $1.74 Million - $2.31 Million
-58,031 Reduced 99.6%
235 $7,000
Q3 2021

Nov 15, 2021

BUY
$30.02 - $39.87 $7,054 - $9,369
235 New
235 $8,000

Others Institutions Holding ADPT

About Adaptive Biotechnologies Corp


  • Ticker ADPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 142,872,992
  • Market Cap $726M
  • Description
  • Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...
More about ADPT
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.